Late last year, Sanofi’s MS drug Lemtrada was slapped down by the FDA. Sanofi investigators now tell FierceBiotech that two years after patients in Phase III studies received their last course of treatment, many are still clearly benefiting from the drug.

…read more

Source: Sanofi’s MS team rebuilds its case for the FDA-rejected MS drug Lemtrada